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Background: Forkhead Box P3 (Foxp3) is a regulatory T cells marker, and its expression correlates with prognosis in
a number of malignancies. The aim of this study is to determine the relationship of Foxp3 expression with
clinicopathological parameters and prognosis in oral squamous cell carcinoma (OSCC).
Methods: Foxp3 expression was examined using immunohistochemistry (IHC) in paraffin-embedded tissue samples
from 273 OSCC patients. Statistical analysis was performed to evaluate the associations between Foxp3 expression,
the clinicopathologic characteristics and prognostic factors in OSCC.
Results: Foxp3 protein expression was significantly associated with lymph node metastasis (P <0.01). Both
univariate and multivariate analyses revealed that Foxp3 was an independent factor for both 5 years overall survival
(OS) and relapse-free survival (RFS) (both P <0.01). Patients with Foxp3 overexpression had shorter OS and RFS.
Conclusions: Our results determined that elevated Foxp3 protein expression was a predictive factor of outcome in
OSCC and could act as a promising therapeutic target.
Keywords: Oral squamous cell carcinoma (OSCC), Foxp3, Five years overall survival, Relapse-Free Survival(RFS)Background
Consisting 90 % of oral malignancies, oral squamous cell
carcinoma (OSCC) is one of the leading causes of
cancer-related death worldwide due to poor prognosis.
The annual estimated occurrence of lip and oral cavity
malignancies is around 400,000 cases [1]. Despite a
rapidly growing number of treatment options, the 5-year
survival rate of OSCC still remains under 60 %. Apart
from classification of differentiation and TNM stage
there are as yet hardly any predictive factors for progno-
sis in patients with OSCC. In this situation it is of
utmost importance to identify potential molecular
markers and targets which provide the necessary condi-
tion of accurate prediction of 5 years overall survival
(OS) and relapse-free survival (RFS) [2].* Correspondence: chengbin@mail.sysu.edu.cn; wangzh75@mail.sysu.edu.cn
†Equal contributors
1Guanghua School of Stomatology, Guangdong Provincial Key Laboratory of
Oral Diseases, Sun Yat-sen University, No. 56, Lingyuan West Road,
Guangzhou 510055, China
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This artic
International License (http://creativecommons
reproduction in any medium, provided you g
the Creative Commons license, and indicate if
(http://creativecommons.org/publicdomain/zeForkhead Box P3 (Foxp3) has played a key role in the
immunosuppressive functions in Tregs and a marked
molecule of Tregs as well [3]. The presence of Foxp3
expression in cancer cells has been proved to be associ-
ated with tumor biological behaviors regulation [4]. A
series of studies have illustrated that the mutation or loss
of Foxp3 might lead to a high rate of tumor formation,
such as developing in mammary [5] or prostatic [6]
epithelial tissues, which indicated Foxp3 as an oncosup-
pressive factor. Moreover, high tumor Foxp3 levels in
tumor cells are also found to be related to better outcome
of cancer patients of gastric cancer [7] and Her2-positive
breast carcinoma [8]. In contrast, only two retrospective
studies in patients with tongue squamous cell carcinoma
(TSCC) [9] and orohypopharynx squamous cell carcinoma
(OHSCC) [10] have demonstrated accordant results that
high Foxp3 expression was associated with poor overall
survival. Until now, no further studies have been con-
ducted to examine the prognostic significance of Foxp3
expression in OSCC. In the present study, we investigatedle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
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Patients included in the study were 188 males and 85 fe-
males with OSCC treated at the Department of Oral-
Maxillofacial Surgery, Stomatology Hospital Affiliated to
Sun Yat-sen University between 2002 and 2009. Deter-
mination of TNM classification is on basis of the Union
for International Cancer Control 2002 standard
(UICC2002). The end point of this study is that of 5 year
overall survival (OS) and relapse-free survival (RFS).
Pathological examination was performed by two inde-
pendent pathologist according to the 2005 revised
World Health Organization classification of tumors.
Tissue microarrays and IHC testing of patient samples
Tissue microarrays (TMAs) were constructed for 273
patients cohorts using three 2 mm tissue cores col-
lected from areas of OSCC epithelium on each tissue
block. Sections were cut into 4 μm thickness, deparaf-
finized, rehydrated and treated with a peroxidase
block. Foxp3 staining procedures was based on manu-
facturers protocol. Heat-based antigen retrieval was
carried out by microwave treatment in 10 mM citrate
buffer (pH 6.0). The sections were incubated with mouse
monoclonal anti-human Foxp3 (clone AO1042a) dilutedFig. 1 Expression and scoring of Foxp3 in oral squamous cell carcinoma (O
cores indicating the low, medium and high cytoplasmic expression in tum1:200 (Abgent, USA) at 4 °C overnight, followed by incu-
bation with ready to use EnVision HRP-IgG secondary
antibody (DAKO, Denmark) for 30 min. Staining was
developed using 3, 3′-diaminobenzidine (DAB) as a
chromogen substrate. The nuclei were counterstained
with Mayer’s hematoxylin.
Predominantly cytoplasmic staining was observed in
tumor cells. The immunoreactive score (IRS) was calcu-
lated as intensity of the staining reaction multiplied by
the percentage of positive cells. Based on the IRS values,
Foxp3 were scored as low, medium and high [10].
Representative micrographs indicating that medium and
high levels of Foxp3 were found only in malignant tis-
sues, while healthy epithelial tissues displayed only low
levels of Foxp3. Consequently according to the HLA &
Cancer Component of the 12th IHW [11], the results
were confirmed by two experienced pathologists who
were blinded to the clinicopathologic data of the pa-
tients. The whole sections were repeatly operated in the
condition that tissue microarray staining was not typical
represented. Negative controls which were treated with-
out primary antibodies were implemented during each
experimentation.
Statistical analysis
The OS rate was the primary endpoint of this study, and
the secondary endpoint was the relapse-free survival (RFS)
of the OSCC patients. OS was defined as the duration
from the date of each patient’s hospitalization to the date
of death from any cause or to the censoring of the patientSCC) tissue. Representative micrographs from tissue microarray (TMA)
or nest
Table 1 Correlation between the Foxp3 expression and clinicopathological characteristics of OSCC
Clinical pathological feature N Expression of Foxp3
Stain value = 1 Stain value = 2 Stain value = 3 P Value
N = 99 N = 106 N = 68
Age 0.65
<60 133 51 (38.3 %) 49 (36.9 %) 33 (24.8 %)
≥60 140 48 (34.3 %) 57 (40.7 %) 35 (25.0 %)
Sex 0.29
Male 188 63 (33.5 %) 74 (39.4 %) 51 (27.1 %)
Female 85 36 (42.4 %) 32 (37.6 %) 17 (20.0 %)
Smoking 0.84
Yes 132 47 (35.6 %) 50 (37.9 %) 35 (26.5 %)
No 141 52 (36.9 %) 56 (39.7 %) 33 (23.4 %)
Drinking 0.47
Yes 131 45 (34.4 %) 49 (37.4 %) 37 (28.2 %)
No 142 54 (38.0 %) 57 (40.1 %) 31 (21.9 %)
Differentiation 0.30
High 200 73 (36.5 %) 82 (41.0 %) 45 (22.5 %)
Medium 64 23 (35.9 %) 22 (34.4 %) 19 (29.7 %)
Low 9 3 (33.3 %) 2 (22.2 %) 4 (44.5 %)
Tumor site 0.23
Gingiva 52 16 (30.8 %) 19 (36.5 %) 17 (32.7 %)
Tongue 131 50 (38.1 %) 47 (35.9 %) 34 (26.0 %)
Buccal 61 26 (42.6 %) 24 (39.4 %) 11 (18.0 %)
Othersa 29 7 (24.1 %) 16 (55.2 %) 6 (20.7 %)
T stage 0.63
T1-T2 186 68 (36.5 %) 74 (39.8 %) 44 (23.7 %)
T3-T4 87 31 (35.6 %) 32 (36.8 %) 24 (27.6 %)
N stage 0.000***
N0 183 73 (39.9 %) 82 (44.8 %) 28 (15.3 %)
N1-N3 90 26 (28.9 %) 24 (26.7 %) 40 (44.4 %)
Clinical Stage 0.09
I-II 142 55 (38.8 %) 59 (41.5 %) 28 (19.7 %)
III-IV 131 44 (33.6 %) 47 (35.9 %) 40 (30.5 %)
Stain value = 1, low level of Foxp3 expression; Stain value = 2, medium level of Foxp3 expression; Stain value = 3, high levels of Foxp3 expression
aOthers included include hard palate, oropharynx and lips
P value was determined using the Linear-by-Linear Association test. *,P<0.05;**, P<0.01;***, P<0.001
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time from hospitalization to local, regional, distant failure,
or other second primary cancer. All statistical analyses
were conducted using SPSS 22.0 statistical software. The
relationships between Foxp3 expression and the clinico-
pathological characteristics were using Linear-by-Linear
Association test (Age, Differentiation, T stage, N stage,
and Clinical stage), and Pearson’s chi-square test (Gender,
Smoking, Drinking, and Tumor site). Patient survival was
evaluated using the Kaplan-Meier method and compared
using Log-Rank test. Univariate and multivariate Coxregression analyses were performed to analyze the survival
data. Multiple comparison (Wilcoxon Rank Sum test) was
performed to analyze the mean OSCC survival time of
Foxp3 staining value. P-value <0.05 was considered statis-
tically significant.
Results
Association of Foxp3 with lymph node metastasis and
other clinicopathological variables
In a cohort of 273 patients with OSCC, Foxp3 expression
was determined to be low in 99 (36.3 %), medium in 106
Table 2 Univariate Analyses of Selected Characteristics with 5 years Overall Survival (OS) and Relapse-free Survival (RFS) among
Patients with Oral Squamous Cell Carcinoma (N = 273)
Characteristics 5-years OS rate (95 % CI) P Value 5-year RFS rate (95 % CI) P Value
T stage
T1-T2 0.415 (0.256–0.574) 0.212 0.652 (0.540–0.764) 0.034*
T3-T4 0.252 (−0.101–0.605) 0.713 (0.448–0.978)
N stage
N0 0.470 (0.290–0.650) 0.000*** 0.671 (0.548–0.794) 0.584
N1-N3 0.252 (−0.101–0.605) 0.733 (0.623–0.843)
Clinical stage
I-II 0.437 (0.249–0.625) 0.012* 0.627 (0.502–0.752) 0.043*
III-IV 0.303 (0.052–0.554) 0.727 (0.527–0.927)
Foxp3 staining value
1 0.474 (0.268–0.680) 0.000*** 0.701 (0.562–0.840) 0.003**
2 0.611 (0.499–0.723) 0.795 (0.711–0.879)
3 0.162 (0.074–0.250) 0.330 (0.133–0.793)
Abbreviations: 95 % CI 95 % confidence interval
P value was determined using the Log-rank test. *,P<0.05;**, P<0.01;***, P<0.001
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dian age of patients at diagnosis was 60 (range 24–85) and
was followed up for an average of 3.58 years. Our analyses
showed that the level of Foxp3 in OSCC was significantly
correlated with lymph node metastasis (P <0.001), but was
not associated with age, gender, smoking, drinking,
grade of differentiation, tumor site, T stage, Clinical
stage (P >0.05) (Table 1). Notably, the correlation of
Foxp3 with prominent lymph node metastasis positivity
suggested a potential role of Foxp3 in increased inva-
sion and metastasis of OSCC.Table 3 Multivariate COX Regression analysis on factors for OSCC su
Characteristics 5-years OS rate
HR (95 % CI) P V
T Stage
T1 or T2 0.547 (0.331–0.904) 0.0
T3 or T4 Reference
N Stage
N0 0.238 (0.143–0.398) 0.0
N1-N3 Reference
Clinical Stage
I-II 2.503 (1.348–4.649) 0.0
III-IV Reference
Foxp3 Staining Value
1 0.197 (0.123–0.315) 0.0
2 0.271 (0.174–0.422) 0.0
3 Reference
Abbreviations: OS overall survival, RFS, relapse free survival, HR hazard ratio, 95 % CI
P value was determined using Cox proportional-hazards model. *,P<0.05;**, P<0.01;Relationship between Foxp3 expression and prognosis in
OSCC patients
To determine whether Foxp3 expression might be a prog-
nostic predictor in OSCC, we examined Foxp3 expression
levels and the clinical follow-up information in all 273
patients of OSCC by Kaplan-Meier analysis and Log-
Rank test. 126 patients died during the follow-up
period, whereas 147 patients were still alive at the end
of follow-up. The crude and adjusted relative risks of
all-cause mortality in these 273 patients were assessed
by univariate and multivariate analyses. As univariatervival
5-year RFS rate
alue HR (95 % CI) P Value
19* 1.188 (0.483–2.923) 0.707
Reference
00*** 0.614 (0.280–1.347) 0.223
Reference
04** 2.249 (0.865–5.852) 0.097
Reference
00*** 0.451 (0.239–0.849) 0.014*
00*** 0.371 (0.192–0.714) 0.003**
Reference
95 % confidence interval
***, P<0.001
Fig. 2 Survival curves of Foxp3 of OSCC patients. It showed that Kaplan–Meier curves of 5 years Overall Survival (OS) and Relapse-Free Survival
(RFS) of different Foxp3 staining values. PValues among different groups were calculated by the Log-Rank test. There was significant difference
between high Foxp3 staining and either of the other two staining grades
Song et al. BMC Cancer  (2016) 16:530 Page 5 of 7analyses shown in Table 1, the clinicopathological
parameters such as N stage, Clinical stage and Foxp3
expression were related to 5-year OS rate, whereas T
stage, Clinical stage and Foxp3 expression were related
to 5-year RFS rate. Multivariate analyses were used to
reveal that T stage, N stage, Clinical stage and Foxp3
expression were the independent risk factors for OS,
and Foxp3 expression were the most important risk
factor for relapse (Tables 2 and 3; Fig. 2).
The results showed that the median overall survival
time in patients with high levels of Foxp3 expression
(stain value = 3) (14, 2–56 months, n = 68) was signifi-
cantly shorter than that in patients with a low level of
Foxp3 expression (stain value = 1) (43, 4–93 months,
n = 99) (P = 0.000) and medium level of Foxp3 expression
(stain value = 2) (38, 2–81 months, n = 106) (P = 0.000).
Furthermore, the median relapse-free survival time was
markedly longer in the low Foxp3 expression group (39,
2–93 months, n = 99) (P = 0.000) and medium Foxp3
expression group (36, 2–59 months, n = 106) (P = 0.000)
compared to that in the high Foxp3 expression group (11,
1–54 months, n = 68). These results indicated that pa-
tients with high levels of Foxp3 expression have a worse
prognosis than those with low levels of Foxp3 expression
(Table 4). The hazard ratio of 5 years OS for low andTable 4 Multiple comparison with the median OSCC survival time o
Foxp3 Staining Value OS
median time (range) (months)
1 (n = 99) 43 (4–93)
2 (n = 106) 38 (2–81)
3 (n = 68) 14 (2–56)
Reference
Abbreviations: OS overall survival, RFS relapse free survival
P value was determined using Wilcoxon Rank Sum test. *,P<0.05;**, P<0.01;***, P<0.medium Foxp3 expression group are 0.197 (P = 0.000) and
0.271 (P = 0.000), respectively, while that of relapse-free
survival (RFS) for low and medium Foxp3 expression
group are 0.451 (P = 0.014) and 0.371 (P = 0.003) taking
high Foxp3 expression group as reference (Table 3).
Discussion
In the present study, the expression of Foxp3 was inves-
tigated in 273 OSCC tissues by immunohistochemistry.
We found that Foxp3 expression was significantly asso-
ciated with lymph node metastasis and clinical outcome
in OSCC. Considering these findings, we suggest that
Foxp3 is a potential novel marker for prognosis and
represents a therapeutic target for the treatment of
OSCC patients.
Continuous effort has been made to identify molecular
biomarkers that could provide accurate information
regarding OSCC prognosis. While the potential role of
tumor Foxp3 as prognostic biomarker of overall survival
has been previously investigated, only two studies
addressed this issue and draw accordant conclusion that
high Foxp3 expression was associated with poor overall
survival in patients with TSCC and OHSCC respectively
[9, 10]. But the relationship with RFS is not clear. And
no association was found with lymph node metastasis.f Foxp3 staining value
RFS
P Value Mean time (range) (months) P Value
0.000*** 39 (2–93) 0.000***




Song et al. BMC Cancer  (2016) 16:530 Page 6 of 7Takenaka et al. observed that tumor cytoplasm Foxp3
expression was associated with worse relapse-free sur-
vival in breast cancer [12]. In small cell lung cancer,
relapse- free survival in patients with Foxp3-positive
tumor was better with earlier follow-up [13]. Whether
Foxp3-positive cancer cells are relevant to recurrence is
controversial. For all the head and neck squamous cell
carcinoma(HNSCC) types, the relationship of Foxp3
expression with RFS is not clear. This is the first study
to describe the association of Foxp3 expression with
both five years overall survival (OS) and relapse-free sur-
vival (RFS) in OSCC patients. It helps to define the pos-
sible link between the biological function of Foxp3 and
the progression of OSCC.
Moreover, we provided evidence that Foxp3
expressed by OSCC cells might play a role in the me-
tastasis of OSCC. We found that OSCC patients with
high tumor Foxp3 expression had significantly shorter
survival time and more lymphnodes involvement than
other groups. Although no association was found with
lymph node metastasis in the previous TSCC and
OHSCC cohort studies, there is still considerable
amount of evidence available which indicates Foxp3
expression in breast cancer [14], gastric cancer [6],
non-small cell lung cancer [15] and esophageal squa-
mous cell carcinoma [16] is correlated with tumor
metastasis. The molecular mechanism of Foxp3 about
metastasis remained unclear. One study demonstrated
that Foxp3 inhibited breast cancer cell adhesion, inva-
sion and metastasis, while study on the molecular
mechanism revealed that Foxp3 inhibited breast can-
cer metastasis by down-regulating CD44 expression
directly [17]. Further studies are required to elucidate
its mechanism in OSCC.Conclusions
In summary, this study demonstrated that Foxp3 expressed
in OSCC cells were significantly correlated with worse
prognosis of both overall survival and relapse-free survival
in OSCC. Ultimately, these findings provided evidence that
Foxp3 expressed by OSCC cells might play a role in the
invasion of OSCC, and tumoral Foxp3 might be suit-
able as a prognostic marker in OSCC. More studies are
needed to further explore how tumor cells regulating
the metastasis behavior during this interaction, espe-
cially in light of the current anticancer efforts to inter-
fere with Foxp3 expression.Abbreviations
Foxp3, Forkhead Box P3; HNSCC, head and neck squamous cell carcinoma;
IHC, immunohistochemistry; IRS, immunoreactive score; OHSCC,
orohypopharynxsquamous cell carcinoma; OS, overall survival; OSCC, oral
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